However, bone biopsy studies in CKD patients showed only a moderate predictive value of sclerostin on bone turnover [6,7] or bone cellularity (as a proxy of bone turnover) [3], without added diagnostic value to the already established markers of bone turnover. This evidence concerns the gene SOST and chronic kidney disease.